Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Up 669.3% in January

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 52,373 shares, an increase of 669.3% from the January 15th total of 6,808 shares. Currently, 1.7% of the company’s shares are short sold. Based on an average daily volume of 86,857 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 86,857 shares, the short-interest ratio is presently 0.6 days. Currently, 1.7% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,630 shares of the company’s stock after purchasing an additional 17,031 shares during the period. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. 58.41% of the stock is currently owned by institutional investors.

Scinai Immunotherapeutics Price Performance

Shares of SCNI traded up $0.01 during trading hours on Tuesday, hitting $0.80. 14,890 shares of the stock were exchanged, compared to its average volume of 61,800. Scinai Immunotherapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $6.18. The business has a 50-day moving average of $0.90 and a 200-day moving average of $1.22. The firm has a market capitalization of $2.55 million, a P/E ratio of -0.08 and a beta of 1.88.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.